JPMorgan Chase & Co. Has $19.51 Million Stake in Inogen Inc (INGN)

JPMorgan Chase & Co. lifted its position in Inogen Inc (NASDAQ:INGN) by 17.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 79,902 shares of the medical technology company’s stock after purchasing an additional 11,928 shares during the quarter. JPMorgan Chase & Co. owned 0.37% of Inogen worth $19,505,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of INGN. Raymond James & Associates grew its holdings in Inogen by 47.2% during the 2nd quarter. Raymond James & Associates now owns 3,519 shares of the medical technology company’s stock worth $656,000 after acquiring an additional 1,129 shares during the last quarter. California Public Employees Retirement System lifted its position in Inogen by 4.6% during the 2nd quarter. California Public Employees Retirement System now owns 31,149 shares of the medical technology company’s stock valued at $5,804,000 after purchasing an additional 1,376 shares during the period. Northern Trust Corp lifted its position in Inogen by 3.9% during the 2nd quarter. Northern Trust Corp now owns 253,076 shares of the medical technology company’s stock valued at $47,155,000 after purchasing an additional 9,425 shares during the period. United Services Automobile Association lifted its position in Inogen by 19.1% during the 2nd quarter. United Services Automobile Association now owns 3,756 shares of the medical technology company’s stock valued at $700,000 after purchasing an additional 602 shares during the period. Finally, Nisa Investment Advisors LLC acquired a new position in Inogen during the 3rd quarter valued at about $2,063,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on INGN. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $169.00 price target on the stock in a research report on Tuesday, February 5th. BidaskClub upgraded shares of Inogen from a “strong sell” rating to a “sell” rating in a research report on Wednesday, November 28th. ValuEngine downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 1st. Needham & Company LLC increased their price target on shares of Inogen to $280.00 and gave the company a “strong-buy” rating in a research report on Monday, November 26th. Finally, TheStreet cut Inogen from a “b-” rating to a “c+” rating in a research note on Thursday, January 3rd. Four equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Inogen presently has an average rating of “Buy” and an average target price of $224.50.

In related news, Director Raymond Huggenberger sold 8,500 shares of the stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $136.81, for a total transaction of $1,162,885.00. Following the completion of the sale, the director now directly owns 11,297 shares of the company’s stock, valued at approximately $1,545,542.57. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.29% of the stock is currently owned by corporate insiders.

NASDAQ INGN opened at $136.72 on Monday. Inogen Inc has a 52-week low of $110.51 and a 52-week high of $287.79. The company has a market cap of $2.92 billion, a P/E ratio of 104.37, a price-to-earnings-growth ratio of 2.57 and a beta of 1.65.

COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Has $19.51 Million Stake in Inogen Inc (INGN)” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2019/02/11/jpmorgan-chase-co-has-19-51-million-stake-in-inogen-inc-ingn.html.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Story: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply